NYSE:MCKMcKesson Stock Price, Forecast & News

McKesson's stock was trading at $135.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MCK stock has increased by 7.9% and is now trading at $145.80. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for McKesson.

McKesson is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for McKesson.

McKesson will be holding an earnings conference call on Monday, August 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

McKesson Co. (NYSE:MCK) released its quarterly earnings data on Wednesday, May, 20th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $4.10 by $0.17. The firm earned $58.54 billion during the quarter, compared to analysts' expectations of $55.60 billion. McKesson had a return on equity of 41.07% and a net margin of 0.39%. The firm's quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.69 EPS. View McKesson's earnings history.

McKesson declared a quarterly dividend on Wednesday, April 29th. Shareholders of record on Monday, June 1st will be given a dividend of $0.41 per share on Wednesday, July 1st. This represents a $1.64 dividend on an annualized basis and a dividend yield of 1.12%. The ex-dividend date of this dividend is Friday, May 29th. View McKesson's dividend history.

McKesson issued an update on its FY21 earnings guidance on Wednesday, May, 20th. The company provided earnings per share (EPS) guidance of $13.95-14.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $15.48. The company issued revenue guidance of +2-4% to $218.6-222.9 billion, compared to the consensus revenue estimate of $234.49 billion.

15 brokerages have issued twelve-month price targets for McKesson's stock. Their forecasts range from $146.00 to $197.00. On average, they anticipate McKesson's share price to reach $172.21 in the next twelve months. This suggests a possible upside of 18.1% from the stock's current price. View analysts' price targets for McKesson.

Media stories about MCK stock have trended negative on Wednesday, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. McKesson earned a news impact score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about McKesson.

McKesson saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 2,180,000 shares, a decline of 18.7% from the June 15th total of 2,680,000 shares. Based on an average trading volume of 1,840,000 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.4% of the company's shares are short sold. View McKesson's Current Options Chain.

Some companies that are related to McKesson include AmerisourceBergen (ABC), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO) and Owens & Minor (OMI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Gilead Sciences (GILD), CVS Health (CVS), salesforce.com (CRM), UnitedHealth Group (UNH), Johnson & Johnson (JNJ), Allergan (AGN), Bank of America (BAC), AbbVie (ABBV) and Chevron (CVX).

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

McKesson's stock is owned by many different retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.05%), DNB Asset Management AS (0.02%), Pensionfund DSM Netherlands (0.01%), Fulton Bank N. A. (0.01%), Pensionfund Sabic (0.01%) and Legacy Capital Partners Inc. (0.00%). Company insiders that own McKesson stock include Brian S Tyler, Brian Scott Tyler, Britt J Vitalone, Lori A Schechter, M Christine Jacobs, N Anthony Coles and Sundeep G Reddy. View institutional ownership trends for McKesson.

MCK stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Fulton Bank N. A., Groesbeck Investment Management Corp NJ, and Legacy Capital Partners Inc.. Company insiders that have sold McKesson company stock in the last year include Brian S Tyler, Britt J Vitalone, Lori A Schechter, M Christine Jacobs, and Sundeep G Reddy. View insider buying and selling activity for McKesson.

MCK stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Pensionfund DSM Netherlands, Pensionfund Sabic, Clarius Group LLC, and Ellevest Inc.. View insider buying and selling activity for McKesson.

Shares of MCK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MCK stock can currently be purchased for approximately $145.80.

McKesson has a market capitalization of $23.64 billion and generates $231.05 billion in revenue each year. The company earns $900 million in net income (profit) each year or $14.95 on an earnings per share basis. McKesson employs 80,000 workers across the globe.

The official website for McKesson is www.mckesson.com.

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The company can be reached via phone at 972-446-4800 or via email at [email protected]